SPY765.44+0.37%QQQ742.99+0.44%BTC/USD83,534.01−0.11%DIA510.22+0.33%GLD380.64−0.05%TLT77.83+0.06%
Benzinga

Health Catalyst Inc

HCATNASDAQ
Trade with Public
Trade with Public
$1.73
-0.02-1.14%
At close: Sep 30, 5:00 PM EST
$1.78
0.052.89%
After Hours: Sep 29, 7:46 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Health Catalyst Analyst Price Targets

Wall Street analyst price targets and consensus rating for Health Catalyst (HCAT).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

3Buy
8Hold
Consensus RatingOverweight# Analysts11Avg. Consensus PT$5Upside to Avg. PT+170.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026Canaccord GenuityRichard CloseDowngradeBuy→Hold$3→$2
Aug 13, 2026Wells FargoStan BerenshteynPT CutEqual-Weight$2→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
Avi Kapoor

PRO
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5

Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $1.75 to $1.5.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75

Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and raises the price target from $1 to $1.75.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved